Mentions
Extended reach
Total likes
Video views
AI synopsis
Several mentions, such as the articles and social discussions, emphasize the significance of the ATTAIN-MAINTAIN trial, highlighting that oral orforglipron can maintain a large portion (75-79%) of weight loss after stopping injectable treatments, with tone and wording expressing optimism. The use of terms like 'game-changer' and references to regulatory approval support the high impact, while phrases like 'promising' and detailed mention of study results reflect strong interest and engagement.
Many mentions praise the trial results and the efficacy of orforglipron in maintaining weight loss, with some highlighting its potential to be a game-changer.
The discussions cover key points like weight maintenance after injectable treatments and the drug's oral form, indicating high curiosity and relevance.
While many mentions are informative and discuss study results and implications, they tend to be more descriptive than deeply analytical, hence a slightly lower engagement score.
Mentions frequently cite significant study findings, approval processes, and potential to change obesity treatment, indicating high overall impact on medical practice and public perception.
Two new randomized studies just published @naturemedicine.bsky.social for weaning from injectable GLP-1 drugs to maintain weight loss —Pill, orforglipron nature.com/articles/s41... —Bacterial supplement for modulating the gut microbiome nature.com/articles/s41...
https://t.co/kAKkIh1WxA Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial #ECO2026 https://t.co/MCxE3lwv8J
www.nature.com/articles/s41... ?
【注目HL】医学：体重減少後の維持に役立つ可能性のある戦略 https://t.co/i7z8Sc9PWL Louis Aronneらの@NatureMedicine #OA #論文 Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial https://t.co/HVTgV7pqnn #オープンアクセス https://t.co/71WbxjI50J
【注目HL】医学：体重減少後の維持に役立つ可能性のある戦略 https://t.co/i7z8Sc9PWL Louis Aronneらの@NatureMedicine #OA #論文 Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial https://t.co/HVTgV7pqnn #オープンアクセス https://t.co/QieHUg9D8w https://t.co/PkByRua9YQ
【注目HL】医学：体重減少後の維持に役立つ可能性のある戦略 https://t.co/i7z8ScanMj Louis Aronneらの@NatureMedicine #OA #論文 Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial https://t.co/HVTgV7pYcV #オープンアクセス https://t.co/nzsBtTtvR8
Planning to stop Wegovy or Zepbound? This video outlines a five-step plan based on clinical trial data to help maintain weight loss after discontinuing GLP-1 medications, including dose management, setting regain…
Weissenberg et al. present the first pivotal study on the oral GLP-1 receptor agonist, orforglipron, showing its ability to sustain weight loss after stopping injectable treatments. The 52-week trial highlights its…
Orforglipron, an oral GLP-1 receptor agonist, effectively maintains significant weight loss over one year in participants previously treated with tirzepatide or semaglutide. The trial highlights its potential safety and…
Emagrecer com uma caneta e depois manter o resultado com um comprimido: onde termina a expectativa e começa a evidência? Nesta análise, o orforglipron, um agonista oral do receptor de GLP-1, mostrou eficácia na…
"비만 주사 끊었다고 요요 와서 날 또 부풀리면 어떡해!" Recent scientific breakthroughs reveal two effective methods to prevent weight regain after dieting. These include an oral medication called orforglipron and beneficial gut bacteria to…
Orforglipron, now FDA-approved under the name Foundayo, offers a new oral option for weight loss maintenance. This video reviews how it compares to injectable GLP-1 medications like semaglutide and tirzepatide, and…
Weight maintenance is a challenging topic for both clinicians and patients. This episode features insights from Dr. Neil Skolnik and Dr. Jamie Almondoz on toxic narratives in weight loss and the latest strategies for…
Welcome to the latest episode of DOC Updates, reviewing recent research on diabetes, obesity, and cardiometabolic health. Key studies include CagriSema and Retatrutide efficacy, CGM benefits beyond insulin users, and…
Until when I have to use the weight loss pen? This question is common among those considering or using obesity treatments. Obesity is a chronic disease, often requiring prolonged therapy. Stopping treatment can lead to…
Full appraisal: https://youtu.be/t3gFmGmUYkE ATTAIN-MAINTAIN is a phase 3b RCT examining whether oral GLP-1 receptor agonist orforglipron can sustain weight loss post tirzepatide or semaglutide treatment. Over 52 weeks…
ATTAIN-MAINTAIN is a phase 3b trial assessing whether oral GLP-1 receptor agonist orforglipron can preserve weight loss achieved with tirzepatide or semaglutide. After 52 weeks, orforglipron maintained significantly…
Orforglipron, an oral GLP-1 receptor agonist, was effective in maintaining significant body weight reduction over one year. Participants retained around 75-79% of their weight loss, offering a safe and convenient…
This video reviews the first head-to-head randomized trial comparing tirzepatide and semaglutide for weight loss in adults without diabetes. It discusses 72-week results, the significance of findings, and critical study…
Can oral orforglipron preserve weight loss after stopping tirzepatide or semaglutide? The Phase 3b ATTAIN-MAINTAIN trial found that selected adults maintained around 75-79% of their weight reduction over 52 weeks, with…
【注目HL】医学：体重減少後の維持に役立つ可能性のある戦略 https://t.co/i7z8Sc9PWL Louis Aronneらの@NatureMedicine #OA #論文 Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial https://t.co/HVTgV7pqnn #オープンアクセス https://t.co/QieHUg9D8w https://t.co/PkByRua9YQ
Medicine: Strategies that may help keep weight off https://t.co/A6JvD0xnWg @NatureMedicine #OA #OpenAccess by Louis J. Aronne Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial https://t.co/j7trEh56ri @weillcornell https://t.co/rwQaEkylll https://t.co/Qe6OVM9531
Coming off tirzepatide or semaglutide didn't erase the weight loss. A year later in ATTAIN-MAINTAIN, placebo had kept roughly a third to a half of it; oral orforglipron held 75-79%. No arm continued the shot, a key limit. https://t.co/72fWgZzeTn
www.nature.com/articles/s41... ?
【注目HL】医学：体重減少後の維持に役立つ可能性のある戦略 https://t.co/i7z8Sc9PWL Louis Aronneらの@NatureMedicine #OA #論文 Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial https://t.co/HVTgV7pqnn #オープンアクセス https://t.co/71WbxjI50J
Medicine: Strategies that may help keep weight off https://t.co/A6JvD0xVLO @NatureMedicine #OA #OpenAccess by Louis J. Aronne Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial https://t.co/j7trEh5EgQ @weillcornell https://t.co/KRXGO79kEe
Orforglipron, an oral GLP-1 receptor agonist, shown effective for weight loss during ATTAIN-MAINTAIN trial with phase 3b results. PMID:42120723, Nat Med 2026, @NatureMedicine https://doi.org/10.1038/s41591-026-04386-7 #Medsky #Pharmsky #RNA #ASHG #ESHG ?
RT @CristobMorales: https://t.co/kAKkIh1WxA Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b AT…
【注目HL】医学：体重減少後の維持に役立つ可能性のある戦略 https://t.co/i7z8ScanMj Louis Aronneらの@NatureMedicine #OA #論文 Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial https://t.co/HVTgV7pYcV #オープンアクセス https://t.co/nzsBtTtvR8
Medicine: Strategies that may help keep weight off https://t.co/A6JvD0xnWg @NatureMedicine #OA #OpenAccess by Louis J. Aronne Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial https://t.co/j7trEh56ri @weillcornell https://t.co/0thvC1lpzs
RT @CristobMorales: https://t.co/kAKkIh1WxA Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b AT…
RT @CristobMorales: https://t.co/kAKkIh1WxA Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b AT…
RT @CristobMorales: https://t.co/kAKkIh1WxA Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b AT…
RT @CristobMorales: https://t.co/kAKkIh1WxA Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b AT…
RT @CristobMorales: https://t.co/kAKkIh1WxA Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b AT…
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial | Nature Medicine?✅ https://t.co/oiTYVUGRnP
?️ Obesity Treatment · ? peptide, Tirzepatide ? Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial ? Louis J. Aronne, Deborah B. Horn, Carel W. le Roux ? 2026-05-12 · Nature Medicine ? Summary: Orforglipron, a once-daily oral medication, helped people maintain weight loss over 52 weeks, with 74.7-79.3% of weight reduction maintained compared to 49.2-37.6% with a placebo. This was observed in two cohorts of participants who had previously achieved weight loss with other medications. ? Consider talking to your doctor about orforglipron if you have lost weight and are looking for a medication to help maintain your weight loss. ? AI Analysis: Breaking news in obesity treatment: a new oral medication called orforglipron has been shown to help people maintain weight loss over time. This could be a game-changer for those strugg
RT @CristobMorales: https://t.co/kAKkIh1WxA Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b AT…
Strategies for maintaining weight lost following injectable treatment or via dieting are described in two unrelated randomised controlled trials published in @natmed.nature.com. spklr.io/63325EzggV and spklr.io/63328Ezggk #medsky ?⚕️
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial https://t.co/1VXiYHHdcS The next big thing? And some media: https://t.co/j7FRYGhUQQ "Daily pill to help keep weight off after stopping obesity jabs"
https://t.co/kAKkIh1WxA Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial #ECO2026 https://t.co/MCxE3lwv8J
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial ->Nature | More on "Orforglipron weight loss maintenance trial" at BigEarthData.ai
Two new randomized studies just published @naturemedicine.bsky.social for weaning from injectable GLP-1 drugs to maintain weight loss —Pill, orforglipron nature.com/articles/s41... —Bacterial supplement for modulating the gut microbiome nature.com/articles/s41...
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. May 13, 2026. Tirzepatide for maintenance ...
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial, Nat Med (2026) [PubMed abstract] ...
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. L.J. Aronne, … N.A. Xavier. Nature ...
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial · Article · Full-text available. May 2026. ·.
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. (2026) Epub ahead of print ...
, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial . Nat Med . 2026. ;. 32. (. 7. ):.
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nature Medicine, 32(7), 2679-2687 ...
... Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nature Medicine. Available from https ...
... 10.1038/s41591-025-04124-5. Weight-loss-independent actions of GLP-1 ... 026-04386-7. Salive ME, Tjaden AH, Ames JR, et al. "Lifestyle and Metformin ...
The following authors, editors, and contributors to the publication were employees of, consultants to, or received compensation from Lilly: Louis J. Aronne, ...
10.1038/s41591-026-04386-7. Contributors: Louis J. Aronne; Deborah B. Horn; Carel W. le Roux; Ariana M. Chao; Wayne Ho; Bruno Halpern; Ryan Griffin; Cathy ...
NATURE MEDICINE 10.1038/s41591-026-04386-7; Franks, PW; Suliman, SGI; Timpson ... NATURE MEDICINE 10.1038/s41591-026-04363-0; le Roux, CW; Wharton, S ...
), 10.1038/s41591-026-04386-7 · Google Scholar. [12]. T.A. Wadden, P. Hollander, S. Klein, K. Niswender, V. Woo, P.M. Hale, L. Aronne. Weight maintenance and ...
doi:10.1038/s41591-026-04386-7. ATTAIN-MAINTAIN directly examines whether oral orforglipron can preserve weight loss after discontinuation of injectable GLP ...
doi:10.1038/s41591-026-04386-7. (Open in a new window)Web of Science ®(Open ... Stevens J, Truesdale KP, McClain JE, Cai J. The definition of weight maintenance.
... s41591-026-04386-7) ." Nat Med(2026) doi: 10.1038/s41591-026-04386-7 (https://www.nature.com/articles/s41591-026-04386-7) • Salive ME, Tjaden AH, Ames JR ...
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ... Incretins have improved the management of obesity...
這結果，為我們在減重的下半場提供 了一項不復胖的利器。 參考資料: https://doi.org/10.1038/s41591-026-04386-7 · Магчыма, гэта відарыс тэкст: "使用猛健樂或過織達 ...
參考資料: https://doi.org/10.1038/s41591-026-04386-7 · Pode ser uma imagem de texto que diz "使用猛健樂或過織. MESSENGER. 何國榮醫師. Médico/a. ?. ENVIAR ...
https: //doi.org/10.1038/s41591-026-04386-7 3. Kansakar, U., Jankauskas, S. S., Pande, S., et al. (2026). Orforglipron: A comprehensive review of an oral ...
doi: 10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #obesidad #GLP1 #saludmetabolica ...
Orforglipron for Maintenance of Body Weight Reduction: The Double-Blind, Randomized Phase 3b ATTAIN-MAINTAIN Trial. Nature Medicine. May 13, 2026. SHARE ...
DOI: 10.1038/s41591-026-04386-7. Study Question Can once-daily oral orforglipron maintain weight-loss benefits in individuals who have achieved a weight ...
org/10.1038/s41591-026-04394-7. doi:10.1038/s41591-026-04386-7. 英語の原文. 「Nature 関連誌注目のハイライト」は、ネイチャー広報部門が報道関係者向けに作成した ...
doi:10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #obesidad #efectorebote #GLP1 ...
doi:10.1038/s41591-026-04386-7. Artículo científico #Foundayz #Orforglipron #GLP1 #Obesidad #MedicinaDeObesidad PérdidaDePeso ...
doi:10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #obesidad #GLP1 ...
doi:10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #obesidad #GLP1 ...
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat. Med. 2026, 32, 1–9 ...
2026, 32, 1–9, h ps://doi.org/10.1038/s41591-026-04386-7. 59. Eli Lilly and Company. Foundayo™ (orforglipron) | Once-Daily Weight Management ...
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b. PMC.NCBI.NLM.NIH.GOV. Orforglipron for ...
doi: 10.1038/s41591-026-04386-7. Epub 2026 May 13. PMID: 42120723; PMCID: PMC13375559. Next scheduled review date: 8 October 2029. More on ...
doi: 10.1038/s41591-026-04386-7 Berg S et al. Obesity Reviews 2025. doi: 10.1111/obr.13929 #ObesityMedicine #GLP1 #Orforglipron ...
Não constitui venda, oferta, propaganda, prescrição ou incentivo ao uso de medicamentos. Não incentivamos hábitos alimentares perigosos que ...
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ... Incretins have improved the management of ...
doi:10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #obesidad #GLP1 ...
doi:10.1038/s41591-026-04386-7. 4 Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of ...
Orforglipron for Maintenance of Body Weight Reduction: The Double-Blind, Randomized Phase 3b ATTAIN-MAINTAIN Trial. Nature Medicine. May 13 ...
doi: 10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #obesidad #GLP1 ...
... 10.1038/s41591-026-04386-7 4. Foundayo (orforglipron). Informações oficiais de prescrição nos Estados Unidos e comunicado de aprovação pela ...
... 10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #obesidad #GLP1 ...
... 10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #obesidad #GLP1 ...
le Roux, et al.. Nature Medicine . May 13, 2026 . DOI: 10.1038/s41591-026-04386-7 · Primary verification record · Consensus ...
doi: 10.1038/s41591-026-04386-7 Berg S et al. Obesity Reviews 2025. doi: 10.1111/obr.13929 #ObesityMedicine #GLP1 #Orforglipron ...
... 10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #GLP1 #obesidad ...
doi:10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #obesidad #efectorebote #GLP1 ...
doi:10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #obesidad #efectorebote #GLP1 ...
2026; 32:2679-2687. doi:10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #GLP1 ...
doi:10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #GLP1 #obesidad ...
Orforglipron for maintenance of body weight reduction (ATTAIN-MAINTAIN). Nat Med. 2026;32:2679-2687. doi:10.1038/s41591-026-04386-7 ℹ️ ...
2026;32:2679-2687. doi: 10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #obesidad ...
... 10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #obesidad #efectorebote #GLP1 ...
... Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026;32:2679 ...
doi:10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #obesidad #GLP1 ...
doi:10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #obesidad #efectorebote #GLP1 ...
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Article Open access 13 ...
doi: 10.1038/s41591-026-04386-7. Epub 2026 May 13. PMID: 42120723; PMCID: PMC13375559. * Horn DB, Kahan S, Batterham RL, Cao D, Lee CJ ...
doi: 10.1038/s41591-026-04386-7. Epub 2026 May 13. PMID: 42120723; PMCID: PMC13375559. * Inamine S, Uesato Y. GLP-1 Receptor Agonist Therapy ...
doi: 10.1038/s41591-026-04386-7 Berg S et al. Obesity Reviews 2025. doi: 10.1111/obr.13929 #ObesityMedicine #GLP1 #Orforglipron ...
doi: 10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #obesidad #efectorebote #GLP1 ...
DOI: 10.1038/s41591-026-04386-7 Eli Lilly press release (May 2026) — TRIUMPH-1 phase 3: retatrutide 28.3% at 80 weeks, 30.3% at 104 weeks (12 mg) ...
... 10.1038/s41591-026-04386-7. PMID: 42120723. Summary for healthcare professionals. No substitute for the full paper or your own clinical ...
doi:10.1038/s41591-026-04386-7. Artículo científico #Foundayz #Orforglipron #GLP1 #Obesidad #MedicinaDeObesidad PérdidaDePeso ...
But maintenance still needs a plan. Research shows that stopping GLP-1 medications can lead to weight regain. But newer studies are also showing ...
7 (2026): 2679–2687, https://doi.org/10.1038/s41591-026-04386-7. 10.1038/s41591-026-04386-7. CAS PubMed Web of Science® Google Scholar. 44 ...
Orforglipron for maintenance of body weight reduction: The double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nature Medicine, 32 ...
... 10.1038/s41591-026-04386-7. [CROSSREF] [Google Scholar]. Aronne LJ, Sattar N, Horn DB et al (2024) Continued treatment with tirzepatide for ...
... Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nature Medicine, 2026.".
... 10.1038/s41591-026-04386-7 3. Kansakar, U., Jankauskas, S. S., Pande, S., et al. (2026). Orforglipron: A comprehensive review of an oral ...
.com/journals/jama/fullarticle/2777886) . JAMA 2021;325;(14):1414-1425 Orforglipron for maintenance of body weight reduction: the double-blind ...
... Orforglipron for maintenance of body weight reduction: The double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. https://doi.org/10.1038 ...
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026 ...
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nature Medicine nature ...
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Medicine (2026) ...
doi:10.1038/s41591-026-04386-7. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity ...
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial people who switched from ...
Dr Miguel Angel Rodriguez hola pregunta yo estoy con wegoby soy deabetica m la recetó el Endocrinólogo siento lo contrario ansiedad de estar ...
doi:10.1038/s41591-026-04386-7. Available from: https://www.nature.com/articles/s41591-026-04386-7; Eli Lilly and Company. Foundayo ...
Orforglipron for maintenance of body weight reduction: The double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nature Medicine. Eli ...
... phase 3b ATTAIN-MAINTAIN trial. Nature Medicine. 2026;32:2679-2687. DOI: 10.1038/s41591-026-04386-7. Pilar Mongelós and 13 others · 14.
The speaker explains that this oral medication is a non- injected GLP-1 agent that works by absorbing the body's blood flow. The video includes ...
... Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial - Nature Medicine ...
... Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial - Nature Medicine ...
... Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial - Nature Medicine ...
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ... Incretins have improved the management of ...
... Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial - Nature Medicine ...
... Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial - Nature Medicine ...
Orforglipron for maintenance of body weight reduction: the double blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026. https ...
... Orforglipron for Maintenance of Body Weight Reduction: The Double-Blind, Randomized Phase 3b ATTAIN-MAINTAIN Trial. Nat Med. 2026 ...
Nat Med. 2026;13:1–9. https://doi.org/10.1038/s41591-026-04386-7. Article CAS Google Scholar.
" Nat Med(2026) doi: 10.1038/s41591-026-04386-7 (https://www.nature.com/articles/s4159...) • Salive ME, Tjaden AH, Ames JR, et al ...
Two studies published in Nature Medicine suggest new approaches that could help maintain weight loss after dieting or injectable treatments. In ...
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026 May 13 ...
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Abstract. Incretins have ...
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026 ...
... Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial” Nature Medicine #saude ...
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026 ...
... 10.1038/s41591-026-04386-7. 3. Gallagher A. FDA Approves Orforglipron For Chronic Weight Management. Drug Topics. April 1, 2026. Accessed May ...
Orforglipron for maintenance of body weight reduction: the ATTAIN-MAINTAIN trial. Nature Medicine. https://doi.org/10.1038/s41591-026-04386-7.
nature.com: "Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial". (Stand ...
doi: 10.1038/s41591-026-04386-7 Berg S et al. Obesity Reviews 2025. doi: 10.1111/obr.13929 #ObesityMedicine #GLP1 #Orforglipron ...
doi: 10.1038/s41591-026-04386-7 Berg S et al. Obesity Reviews 2025. doi: 10.1111/obr.13929 #ObesityMedicine #GLP1 #Orforglipron ...
New findings from ATTAIN-MAINTAIN: A Phase 3b study examining maintenance of body weight reduction in adults with obesity or overweight with ...
Die Ergebnisse wurden in Nature Medicine veröffentlicht (2026; DOI: 10.1038/s41591-026-04386-7). Orforglipron ist ein oral verfügbarer ...
... 10.1038/s41591-026-04386-7 참고 논문 2 (장내 유익균): Nature Medicine (2026) "Pasteurized Akkermansia muciniphila MucT for weight loss ...
doi: 10.1038/s41591-026-04386-7 Berg S et al. Obesity Reviews 2025. doi: 10.1111/obr.13929 #ObesityMedicine #GLP1 #Orforglipron ...
doi:10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #obesidad #efectorebote #GLP1 ...
... 10.1038/s41591-026-04386-7 ClinicalTrials.gov: NCT06584916 BGM "Thinking Music" by Kevin MacLeod (incompetech.com) — CC BY 4.0 ?️ ...
Ylva Trolle Lagerros diskuterar vikthållning efter obesitasbehandling och nya studier om injektioner och GLP1-tabletter för långsiktig ...
"Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial" - Nature Medicine
... Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial - Nature Medicine ...
doi:10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #obesidad #GLP1 ...
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Epocrates Logo. 1 in 5 ...
Orforglipron for Maintenance of Body Weight Reduction: The Double-Blind, Randomized Phase 3b ATTAIN-MAINTAIN Trial. Nature Medicine. May 13 ...
... orforglipron-for-maintenance-of-body-weight-reduction-the-double-blind-randomized-phase-3b-attain-maintain-trial/. Log in. Walter's post.
Nat Med. 2026;10.1038/s41591-026-04386-7. Featured image: Andreas Prott on Adobe Stock. Author:.
DOI: 10.1038/s41591-026-04386-7, https://www.nature.com/articles/s41591-026-04386-7. Be the first to rate this article. Posted in: Drug Trial ...
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med (2026). https ...
DOI: 10.1038/s41591-026-04386-7. Journal information: Nature Medicine. Key medical concepts. orforglipronObesitySemaglutideTirzepatide ...
2026;doi:10.1038/s41591-026-04386-7. Disclosures: Aronne reports receiving grants or personal fees from Altimmune, AstraZeneca, Boehringer ...
doi: 10.1038/s41591-026-04386-7. 英語の原文. 「注目のハイライト」は、ネイチャー広報部門が報道関係者向けに作成したプレスリリースを翻訳した ...
Close menu. ATTAIN-MAINTAIN study: https://www.nature.com/articles/s41591-026-04386-7 · Like · Reply. 1 Reaction. Joao Monteiro, graphic. Joao ...
Sharing this exciting news from Dr. Deborah Bade Horn ! SURMOUNT Maintain and ATTAIN Maintain studies have been published in The Lancet and ...
... 維持約38%。 圖片來自： DOI: 10.1038/s41591-026-04386-7 #ECO2026. No photo description available. 9 · Like ...
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial - Nature Medicine. r ...
doi:10.1038/s41591-026-04386-7. ↵. Wise J . New weight loss pill outperforms oral semaglutide for diabetes patients, study reports. BMJ 2026 ...
was published in Nature Medicine at 23:00 UK time on Tuesday 12th of May 2026. DOI: https://doi.org/10.1038/s41591-026-04386-7. Declared ...
Weightmaintenance and improved cardiometabolic health! This morning #SURMOUNTMAINTAIN was published in the #LANCET and #ATTAINMaintain in ...
... Orforglipron for maintenance of body weight reduction: the double-blind ...
Interesting in Nature Medicine: Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN ...
... Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial - Nature Medicine ...
... Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial - Nature Medicine ...
doi:10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #obesidad #GLP1 ...
... Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial - Nature Medicine ...
... Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial - Nature Medicine ...
For those of us who work in IBD; the conversation around GLP-1 drugs in this patients is moving fast, whether we work at the pharma industry ...
... Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial - Nature Medicine ...
Interesting in Nature Medicine: Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN ...
... Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026;32:2679 ...
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026 ...
doi:10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #obesidad #GLP1 ...
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026 ...
doi:10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #GLP1 #obesidad ...
doi:10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #obesidad #efectorebote #GLP1 ...
doi:10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #obesidad #efectorebote #GLP1 ...
... https://doi.org/10.1038/s41591-026-04386-7 · May be an image of text that says '使用猛健樂或過織. MESSENGER. 何國榮醫師. Doctor. ?. SEND ...
doi:10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #obesidad #GLP1 ...
doi:10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #obesidad #GLP1 ...
SLIM GOLD ✨ Poderoso inibidor de apetite Auxilia na redução da gordura localizada Combate a retenção de líquidos ⚡ Acelera o ...
doi:10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #obesidad #efectorebote #GLP1 ...
doi:10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #obesidad #efectorebote #GLP1 ...
doi:10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #obesidad #GLP1 ...
doi:10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #obesidad #efectorebote #GLP1 ...
doi:10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #obesidad #GLP1 ...
doi:10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #obesidad #efectorebote #GLP1 ...
doi:10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #obesidad #efectorebote #GLP1 ...
Solo les dan este medicamento a las personas que tienen azúcar, ? Yo tengo hipotiroidismo pero tengo mucho sobrepeso . 42w · 1 like.
doi:10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #obesidad #efectorebote #GLP1 ...
doi:10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #GLP1 #obesidad ...
Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial Louis J. Aronne, Deborah ...
DOI: 10.1038/s41591-026-04386-7. View all 2 comments · 2 days ago · diabetesyestilodevida's profile picture. dr.danielzamorano's profile picture.
doi:10.1038/s41591-026-04386-7 ℹ️ Contenido educativo. No sustituye la consulta médica profesional. #orforglipron #obesidad #GLP1 ...
https: //doi.org/10.1038/s41591-026-04386-7 3. Kansakar, U., Jankauskas, S. S., Pande, S., et al. (2026). Orforglipron: A comprehensive ...
org/10.1038/s41591-026-04386-7 3. Kansakar, U., Jankauskas, S. S., Pande, S., et al. (2026). Orforglipron: A comprehensive review of an oral ...
ET
CM
JI
NJ
NP
MN
SG
D
DJ
W
YL
DF
MT
RN
JF
P
JR
SN
PW
CA